Upcoming updates
for 2025-2026
Pharmacotherapy Bipolar Depression: Strategies for Everyday Management
Quick Take Vol. 82
Lithium: How to Manage Dosage and Side Effects – Interview
Hyponatremia and Antidepressants
GI Side Effects and Antidepressants
Quick Take Vol. 83
Managing Catatonia: From Clinical Assessment to Effective Intervention – Interview
Treatment-Resistant Obsessive-Compulsive Disorder (Update)
Quick Take Vol. 84
Addiction Psychopharmacology in Patients with Medical Comorbidities
Pharmacotherapy of treatment-resistant depression – Interview
Tricyclic Antidepressants in Psychiatry
Management of Psychotropic-Induced Sexual Dysfunction
Quick Take Vol. 85
Nutritional Psychiatry – Interview
Antidepressant-Induced Excessive Sweating
Side Effects of Antidepressants Part 5 (Hyperprolactinemia)
Prescribing for mental health conditions in patients with physical illness
Quick Take Vol. 86
Ketamine and Esketamine
Quick Take Vol. 87
Posttraumatic Stress Disorder Psychopharmacology Algorithm (Update)
Metabolic Psychiatry
Use of Long-Acting Injectable Antipsychotics in Schizophrenia – Interview
Pharmacotherapy for Cannabis Use Disorder
Quick Take Vol. 88
Pharmacotherapy of Alcohol Use Disorder – Interview
Quick Take Vol. 89
Treatment-Resistant Anxiety Disorders: Focus on GAD, PD, and SAD
Antidepressant Withdrawal Effects and Safe Deprescribing – Interview
Pharmacotherapies for Stimulant Use Disorder (Update)
Quick Take Vol. 90
Mood and Anxiety Disorders During Perimenopause – Interview
Nutraceuticals and Phytoceuticals for Mood and Anxiety Disorders
Quick Take Vol. 91
Updates on Geriatric Psychopharmacology – Interview
Advanced Perinatal Psychopharmacology: Anxiety Disorders, PTSD, and Insomnia
Quick Take Vol. 92
Psychotropic-Induced Movement Disorders and Cognitive Side Effects (Update) – Interview
Quick Take Vol. 93
CME Information
Physicians – CME Accreditation Statement
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nursing professionals – CME Accreditation Statement
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour.
Physician assistants – CME Accreditation Statement
The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.
This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Self Assessment for MOC – Accreditation Statement
- Psychopharmacology Institute Self-Assessment Program 2025
Dates: April 1, 2025 – April 1, 2028
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- Psychopharmacology Institute Self-Assessment, 2023- Part 1
Dates: January 1, 2023 – January 1, 2026
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment, 2023- Part 1 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- Psychopharmacology Institute Self-Assessment Program 2024
Dates: April 1, 2024 – April 1, 2027
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.